The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Abstract
AIM: Probably, the most important and potentially lethal adverse event of azathioprine (AZA) and mercaptopurine (MP) is myelosuppression. Our aim was to conduct a review of AZA/MP-induced myelotoxicity in inflammatory bowel disease (IBD) patients. METHODS: Bibliographical searches were performed in MEDLINE/EMBASE. The studies evaluating thiopurine-induced myelotoxicity in patients with IBD were reviewed. The cumulative incidence and the incidence rate of AZA/MP-induced myelotoxicity were calculated by a meta-analysis. RESULTS: In total, 66 studies (8,302 patients) were included. The cumulative incidence of AZA/MP-induced myelotoxicity was 7% (95% confidence interval [CI] 6-8%). The incidence rate (per patient and year of treatment) of the drug-induced myelotoxicity was 3% (95% CI 3-4%). The risk was roughly similar with AZA and with MP (7%vs 9%). The duration of AZA/MP treatment in patients with myelotoxicity ranged from 12 days to 27 yr. The cumulative incidence of infections among AZA/MP-induced myelotoxicity patients was 6.5%. The cumulative incidence of severe myelotoxicity was 1.1% (incidence rate 0.9%). Three deaths were reported due to myelotoxicity (cumulative incidence 0.06%, 95% CI 0.02-0.17%). The risk of death among patients who developed myelotoxicity was 0.94% (95% CI 0.32-2.70%). CONCLUSION: The incidence rate of myelotoxicity in IBD patients receiving AZA/MP is approximately 3% per patient and year of treatment. Although bone marrow toxicity may develop at any time after starting the therapy, this happens more frequently during the first months. The incidence rate of severe myelotoxicity is less than 1% per patient and year of treatment, and the mortality risk is less than 0.1% (which means that the risk of death among IBD patients who develop myelotoxicity is approximately 1%).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Dubinsky, M. C., Lamothe, S., Yang, H. Y., Targan, S. R., Sinnett, D., Théorêt, Y., & Seidman, E. G. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70140-5 · Cited by 996
Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis
Pearson, D. C., May, G. R., Fick, G. H., & Sutherland, L. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-2-199507150-00009 · Cited by 950
Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C.-H., & Evans, W. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2001 · Cited by 733
Markowitz, J., Grancher, K., Kohn, N., Lesser, M., & Daum, F. (2000) · Gastroenterology · doi:10.1053/gast.2000.18144 · Cited by 716
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
Fraser, A. G. (2002) · Gut · doi:10.1136/gut.50.4.485 · Cited by 629
Colombel, J., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J., Bonaz, B., Soulé, J.-C., Modigliani, R., Touze, Y., Catala, P., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70354-4 · Cited by 619
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Metadata
- Authors
- Gisbert, J. P., & Gomolln, F.
- Venue
- The American Journal of Gastroenterology
- Published
- 2008-07
- Volume
- 103
- Issue
- 7
- Pages
- 1783-1800
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2088315857
- Cited by
- 253
- References
- 93
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review. https://app.cochat.ai/papers/10.1111/j.1572-0241.2008.01848.x
- The paper
- Gisbert, J. P., & Gomolln, F. (2008). Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2008.01848.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.